NeoGenomics (NASDAQ:NEO) Issues FY 2025 Earnings Guidance

NeoGenomics (NASDAQ:NEO) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.150-0.190 for the period, compared to the consensus EPS estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.

NeoGenomics Trading Down 2.0 %

Shares of NeoGenomics stock opened at $9.95 on Thursday. The company’s fifty day moving average price is $14.06 and its two-hundred day moving average price is $15.11. The firm has a market capitalization of $1.28 billion, a PE ratio of -16.20 and a beta of 1.23. NeoGenomics has a 52-week low of $8.98 and a 52-week high of $19.11. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. On average, analysts expect that NeoGenomics will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on NEO shares. The Goldman Sachs Group lowered their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Bank of America decreased their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Piper Sandler cut their price target on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Needham & Company LLC dropped their target price on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.60.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.